Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470327 · ClinicalTrials.gov registry record
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
A clinical trial of Idiopathic Pulmonary Fibrosis and Sarcoidosis, sponsored by University of Chicago.
- Recruiting
- Registry status
- 4,000
- Enrollment target
- 1
- Study location
NCT00470327: Recruiting study of Idiopathic Pulmonary Fibrosis and Sarcoidosis, sponsored by University of Chicago.
NCT00470327 is a study of Idiopathic Pulmonary Fibrosis and Sarcoidosis that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 4,000 participants, above the 673-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (494% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00470327, a study of Idiopathic Pulmonary Fibrosis and Sarcoidosis, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Primary Outcome
We assess mortality roughly yearly but duration is unlimited
Conditions Studied
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2005-09 |
| Est. Completion | 2030-12 |
What NCT00470327 shows while recruiting
NCT00470327 is an observational study that tracks outcomes without assigning an intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 673-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (494% higher).
The record links to 4 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT00470327 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00470327 about?
NCT00470327 is a clinical study titled "A Study of the Natural Progression of Interstitial Lung Disease (ILD)". We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of thes...
What is the current status of trial NCT00470327?
This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2005-09. Estimated completion is 2030-12.
What conditions does trial NCT00470327 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Sarcoidosis, Interstitial Lung Diseases, Connective Tissue Disorder.
Who is sponsoring clinical trial NCT00470327?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00470327 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00470327's enrollment target sits among peer trials
4,000 3rd of 51 higher than 49 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma